PGA TOUR Names AbbVie Official Pharmaceutical Sponsor

The PGA TOUR has a new sponsor. 

AbbVie has been named the Official Pharmaceutical Sponsor of the PGA TOUR and the 2026 Presidents Cup. 

Through this new partnership, the company has introduced a multi-year, purpose-driven campaign called ‘Birdies for Brain Health’ which AbbVie is using to raise awareness and advance support for both people living with brain health conditions and their care partners. 

The campaign launches at the 2026 Presidents Cup, and begins with a donation in recognition of the more than one in three people globally who are affected by a neurological disorder, according to the World Health Organisation’s ‘Global Status Report on Neurology’. 

According to AbbVie, this donation will be shared between six patient advocacy organisations that are advancing science, awareness and support across migraine, mental health conditions and Parkinson’s disease.

“Through our latest partnership, Birdies for Brain Health, a multiyear, purpose-driven campaign, we’re working to elevate awareness and support people living with conditions that affect brain health,” Tracie Haas, Senior Vice President of Corporate Affairs of AbbVie, said of the campaign on LinkedIn.

AbbVie's multi-year campaign

In order to bring this marketing campaign to life, AbbVie is working closely with Gary Woodland, a US captain’s assistant for the 2026 Presidents Cup, and a 2019 US Open Champion. 

Gary also underwent a craniotomy in 2023 in order to remove a benign brain lesion, and has since spoken publicly about the physical, mental and emotional challenges he has faced over the course of his recovery – sharing that it was important to “keep fighting” in March 2026 after his first PGA TOUR win since the surgery. 

“Purpose and community impact have long been part of the PGA TOUR's identity, and AbbVie Birdies for Brain Health gives us a meaningful way to build on that legacy,” says Dan Glod, PGA TOUR Executive Vice President of Corporate Partnerships. 

“We are proud to welcome AbbVie as the Official Pharmaceutical Sponsor of the PGA TOUR and the 2026 Presidents Cup, and to use the reach of golf to help raise awareness and support people living with brain health conditions and their care partners.”

Elevating patient voices through marketing

As part of the campaign, through 2027 Birdies for Brain Health is set to scale through donations for every birdie at PGA TOUR Signature Events and the FedExCup Playoffs. 

These donations are set to support organisations such as the American Migraine Foundation, the National Headache Foundation, Mental Health America, the National Alliance on Mental Illness, The Michael J. Fox Foundation for Parkinson’s Research and the Parkinson’s Foundation. 

“Neurological and mental health conditions affect more than the individual living with the disease. They can impact families and entire support networks,” says Tracie. 

“Through our partnership with the PGA TOUR, we have a unique opportunity to elevate patient and care partner voices, support patient advocacy organisations and raise awareness of the critical need for continued research, innovation and care for the communities we serve.”

AbbVie: Projects and partnerships

• Manchester University NHS Foundation Trust (MFT): The purpose of this collaborative working project is to develop and implement a new advanced therapy/biologics dermatology service at MFT to address challenges and improve the service for both the NHS and the patients – delivering improved standards of care for patients with psoriasis and atopic dermatitis. 
• Guy's and St Thomas' NHS Foundation Trust: This partnership is focused on working with both the gastroenterology and pharmacy departments of Guys and St Thomas NHS Foundation Trust to facilitate the optimisation of the journey for patients requiring advanced therapy. Through mapping the whole patient journey, bottlenecks will be identified and can be addressed, the multi-disciplinary team can develop / optimise specialist services and/or clinics.
• Health Innovation Manchester (HInM): AbbVie and HInM are working collaboratively to understand, reimagine and transform care and outcomes for migraine patients across the Greater Manchester (GM) Healthcare System. The objectives are to identify and address the current challenges within the migraine pathway across GM, with a focus on supporting earlier diagnosis, enhancing management and improving patient access to appropriate care whilst driving system efficiencies throughout the migraine pathway.
• Health Innovation North East and North Cumbria (HI NENC): AbbVie and HI NENC are working collaboratively to design, launch and evaluate a pilot that will test the value of an Independent Prescribing (IP) community pharmacy-led Migraine management service across the NENC region. The pilot is intended to assess whether this service model may support improved management of migraine in appropriate patients within primary care, and to identify the operational, digital and service requirements that would need to be considered for any future wider adoption.